The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.
 
Eric Xueyu Chen
Honoraria - AstraZeneca Canada; Bayer; Eisai; Ipsen; Roche Canada
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada
 
Petr Kavan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical
 
Mustapha Tehfe
Honoraria - Bristol-Myers Squibb; Celgene; Eisai; Merck; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Merck; Taiho Pharmaceutical; Takeda
Research Funding - Celgene
 
Jeremy S. Kortmansky
No Relationships to Disclose
 
Michael B. Sawyer
Stock and Other Ownership Interests - AstraZeneca; Gilead Sciences
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; ipsen; Ipsen; LEO Pharma; Merck; Mylan; Novartis; Novartis Canada Pharmaceuticals Inc; nutricia; pfizer; Sanofi; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Celgene; Immuneering; Ipsen; Ipsen; LEO Pharma; Merck; Nutricia; Pfizer; Yinuoke
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer
 
E. Gabriela Chiorean
Consulting or Advisory Role - Axiom Healthcare Strategies; Bayer; BioNTech; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; Ipsen; Merck; Novartis; Noxxon Pharma; Noxxon Pharma; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); FibroGen (Inst); Halozyme (Inst); Lonza (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - HalioDx (Inst); Ipsen (Inst); Pfizer (Inst)
Research Funding - Merck (Inst)
 
Blase N. Polite
Honoraria - American Journal of Managed Care; Genzyme; HMP; Physicans' Education Resource; Simon-Kucher and Partners
Consulting or Advisory Role - Cancer Expert Now
Speakers' Bureau - Natera
Travel, Accommodations, Expenses - Institute for Clinical and Economic Review; Tapestry Pharmaceuticals
 
Lucas Wong
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Exelixis (Inst); FibroGen (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); PledPharma (Inst); Seer (Inst); Seer (Inst); Seer (Inst); SynCoreBio (Inst); Tesaro (Inst)
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; GlaxoSmithKline; Incyte; Pfizer; Seagen; Taiho Pharmaceutical; Zhuhai DL Biotech
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Kristen Renee Spencer
Consulting or Advisory Role - Caris Life Sciences; Helsinn Therapeutics; Lynx Group; QED Therapeutics
 
Jorge Chaves
No Relationships to Disclose
 
Chenxiang Li
Employment - Jazz Pharmaceuticals (I); Merck
Stock and Other Ownership Interests - Jazz Pharmaceuticals (I)
 
David Carpenter
Employment - ICON Clinical Research; Indivior
Stock and Other Ownership Interests - Indivior
 
Pierre Leconte
Employment - MSD Oncology
Stock and Other Ownership Interests - MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; QED Therapeutics; SERVIER; Taiho Oncology
Speakers' Bureau - Incyte; Lilly
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)